| Autor: |
Olivier, Timothée, Haslam, Alyson, Prasad, Vinay |
| Zdroj: |
Translational Oncology; February 2023, Vol. 28 Issue: 1 |
| Abstrakt: |
•Sotorarib was the first KRAS G12C inhibitor to be approved in NSCLC.•CodeBreaK 200 was a phase 3 trial of sotorasib versus docetaxel in the second-line setting.•The control arm was beneath the best standard-of-care, cross-over was problematic.•High rates of censoring make progression-free survival estimates unreliable.•The sample size was lowered: an overall survival decrement cannot be excluded. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
